Cempra, a biotech developing potent antibiotics to fight pneumonia and skin infections, raised $50 million by offering 8.4 million shares at $6, below the range of $11 to $13. The company had originally planned to sell 6 million shares. Cempra plans to list on the NASDAQ under the symbol CEMP. Stifel Nicolaus Weisel, Leerink Swann and Cowen & Company acted as lead managers on the deal.
